463 related articles for article (PubMed ID: 18628473)
1. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts.
Ostermann E; Garin-Chesa P; Heider KH; Kalat M; Lamche H; Puri C; Kerjaschki D; Rettig WJ; Adolf GR
Clin Cancer Res; 2008 Jul; 14(14):4584-92. PubMed ID: 18628473
[TBL] [Abstract][Full Text] [Related]
2. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
[TBL] [Abstract][Full Text] [Related]
3. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts.
Lee J; Fassnacht M; Nair S; Boczkowski D; Gilboa E
Cancer Res; 2005 Dec; 65(23):11156-63. PubMed ID: 16322266
[TBL] [Abstract][Full Text] [Related]
4. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
[TBL] [Abstract][Full Text] [Related]
6. Technology insight: cytotoxic drug immunoconjugates for cancer therapy.
Ricart AD; Tolcher AW
Nat Clin Pract Oncol; 2007 Apr; 4(4):245-55. PubMed ID: 17392715
[TBL] [Abstract][Full Text] [Related]
7. Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens.
Zhang S; Zhang HS; Cordon-Cardo C; Ragupathi G; Livingston PO
Clin Cancer Res; 1998 Nov; 4(11):2669-76. PubMed ID: 9829729
[TBL] [Abstract][Full Text] [Related]
8. Tumor stroma-associated antigens for anti-cancer immunotherapy.
Hofmeister V; Vetter C; Schrama D; Bröcker EB; Becker JC
Cancer Immunol Immunother; 2006 May; 55(5):481-94. PubMed ID: 16220326
[TBL] [Abstract][Full Text] [Related]
9. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
[TBL] [Abstract][Full Text] [Related]
10. Derlin-1 is overexpressed on the tumor cell surface and enables antibody-mediated tumor targeting therapy.
Ran Y; Hu H; Hu D; Zhou Z; Sun Y; Yu L; Sun L; Pan J; Liu J; Liu T; Yang Z
Clin Cancer Res; 2008 Oct; 14(20):6538-45. PubMed ID: 18927294
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody CC188 binds a carbohydrate epitope expressed on the surface of both colorectal cancer stem cells and their differentiated progeny.
Xu M; Yuan Y; Xia Y; Achilefu S
Clin Cancer Res; 2008 Nov; 14(22):7461-9. PubMed ID: 19010863
[TBL] [Abstract][Full Text] [Related]
12. Expression of stromal cell markers in distinct compartments of human skin cancers.
Huber MA; Kraut N; Schweifer N; Dolznig H; Peter RU; Schubert RD; Scharffetter-Kochanek K; Pehamberger H; Garin-Chesa P
J Cutan Pathol; 2006 Feb; 33(2):145-55. PubMed ID: 16420310
[TBL] [Abstract][Full Text] [Related]
13. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.
Tse KF; Jeffers M; Pollack VA; McCabe DA; Shadish ML; Khramtsov NV; Hackett CS; Shenoy SG; Kuang B; Boldog FL; MacDougall JR; Rastelli L; Herrmann J; Gallo M; Gazit-Bornstein G; Senter PD; Meyer DL; Lichenstein HS; LaRochelle WJ
Clin Cancer Res; 2006 Feb; 12(4):1373-82. PubMed ID: 16489096
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors.
Modak S; Kramer K; Gultekin SH; Guo HF; Cheung NK
Cancer Res; 2001 May; 61(10):4048-54. PubMed ID: 11358824
[TBL] [Abstract][Full Text] [Related]
15. A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy.
Müller D; Frey K; Kontermann RE
J Immunother; 2008 Oct; 31(8):714-22. PubMed ID: 18779748
[TBL] [Abstract][Full Text] [Related]
16. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin.
Rettig WJ; Garin-Chesa P; Healey JH; Su SL; Ozer HL; Schwab M; Albino AP; Old LJ
Cancer Res; 1993 Jul; 53(14):3327-35. PubMed ID: 8391923
[TBL] [Abstract][Full Text] [Related]
17. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts.
Hamann PR; Hinman LM; Beyer CF; Lindh D; Upeslacis J; Shochat D; Mountain A
Bioconjug Chem; 2005; 16(2):354-60. PubMed ID: 15769089
[TBL] [Abstract][Full Text] [Related]
18. Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors.
Inamoto T; Yamada T; Ohnuma K; Kina S; Takahashi N; Yamochi T; Inamoto S; Katsuoka Y; Hosono O; Tanaka H; Dang NH; Morimoto C
Clin Cancer Res; 2007 Jul; 13(14):4191-200. PubMed ID: 17634548
[TBL] [Abstract][Full Text] [Related]
19. [Advances in research on monoclonal antibody agents for cancer therapy].
Zhen Y
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Feb; 22(1):9-13. PubMed ID: 12903485
[TBL] [Abstract][Full Text] [Related]
20. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.
Hamann PR; Hinman LM; Beyer CF; Greenberger LM; Lin C; Lindh D; Menendez AT; Wallace R; Durr FE; Upeslacis J
Bioconjug Chem; 2005; 16(2):346-53. PubMed ID: 15769088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
